Drug Profile
Research programme: orphan disease therapeutics - Avalo Therapeutics/The Childrens Hospital of Philadelphia
Alternative Names: MDGN-204; MDGN-206Latest Information Update: 30 Aug 2021
Price :
$50
*
At a glance
- Originator Medgenics; The Childrens Hospital of Philadelphia
- Developer Avalo Therapeutics; The Childrens Hospital of Philadelphia
- Class Gene therapies; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 30 Aug 2021 Cerecor is now called Avalo Therapeutics
- 03 Feb 2020 Aevi Genomic Medicine has been acquired and merged into Cerecor
- 28 Feb 2019 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (SC, Implant)